公开(公告)号：HU222284B1

公开(公告)日：2003-05-28

申请号：HU9603450

申请日：1996-12-13

Applicant: HOECHST AG

Inventor： CRAUSE PETER DR ,  ENGLERT HEINRICH CHRISTIAN DR ,  GERLACH UWE DR ,  GOEGELEIN HEINZ DR ,  KLAUS ERIK DR ,  LINZ WOLFGANG DR ,  MANIA DIETER DR

IPC: C07D311/58 ,  A61K31/35 ,  A61K31/352 ,  A61K31/353 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/4025 ,  A61K31/4412 ,  A61K31/443 ,  A61K31/445 ,  A61P9/00 ,  A61P9/06 ,  A61P9/10 ,  C07D311/64 ,  C07D311/70 ,  C07D405/12 ,  C07D311/20

Abstract: N-(4-Amidoalkyl-chroman-5-yl-sulphonyl)-urea or -thiourea derivatives of formula (I) and their salts are new. R1 = H, alkyl, alkoxy, F, Cl, Br, I, CF3, NH2, mono- or dialkylamino or alkylthio; R2a = H, Me or Et; R2b, R2d = H, Me or Et; or phenyl or benzyl (both optionally ring-substituted by 1-3 of halogen, Me, Et, OMe and OEt); R2c,R2e = H, Me or Et; R3 = H, alkyl, cycloalkyl, cycloalkylmethyl or CF3; n = 1 or 2; Z = O or S; A = phenyl (optionally substituted by 1-3 of halogen, Me, OMe, Et or OEt), a lactam residue of formula (a), 1-oxo-1,2,3,4-tetrahydroisoquinolin-2-yl, 1-oxo-per-hydro-isoquinolin-2-yl, 1-oxo-1,2-dihydro-iso-indol-2-yl or 1-oxo-per-hydro-iso-indol-2-yl; B = 3-6C alkylene or 3-6C alkenylene (both optionally substituted by 1-3 alkyl); unless specified otherwise alkyl moieties have 1-4C and cycloalkyl moieties 3-6C.

公开(公告)号：CZ291094B6

公开(公告)日：2002-12-11

申请号：CZ365896

申请日：1996-12-12

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH CHRISTIAN DR ,  GERLACH UWE DR ,  MANIA DIETER DR ,  LINZ WOLFGANG DR ,  GOGELEIN HEINZ DR ,  KLAUS ERIK DR ,  CRAUSE PETER DR

IPC: C07D311/58 ,  A61K31/35 ,  A61K31/352 ,  A61K31/353 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/4025 ,  A61K31/4412 ,  A61K31/443 ,  A61K31/445 ,  A61P9/00 ,  A61P9/06 ,  A61P9/10 ,  C07D311/64 ,  C07D311/70 ,  C07D405/12

Abstract: In the present invention there are described substituted chromanylsulfonyl(thio)ureas of the general formula I, in which Re1 represents hydrogen, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, a halogen, trifluoromethyl, an amino group, NH-alkyl having 1 to 4 carbon atoms, N(alkyl)2 having 1 to 4 carbon atoms in the identical or different alkyl radicals, or S-alkyl having 1 to 4 carbon atoms; Re2a represents hydrogen or alkyl having 1 or 2 carbon atoms; Re2b and Re2d are each hydrogen, alkyl having 1 or 2 carbon atoms, an optionally substituted phenyl, or optionally substituted benzyl, Re2c and Re2e are each hydrogen or alkyl having 1 or 2 carbon atoms; Re3 represents hydrogen, alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 6 ring carbon atoms, CHi2-cycloalkyl having 3 to 6 ring carbon atoms, or trifluoromethyl; Q denotes (CHi2)n, wherein n is 1 or 2; Z represents sulfur or oxygen; and A denotes an optionally substituted phenyl or a is radical of a saturated or unsaturated lactam a radical of a heterocyclic bicyclic system, and their pharmaceutically acceptable salts. These compounds are valuable pharmaceuticals for the treatment of cardiac arrhythmias and for the prevention of sudden heart death due to arrhythmia. They can be used as antiarrhythmics and are suitable for the prevention of sudden heart death, for the treatment of cardiac insufficiency and also heart failure as a result of the effects of shock. Described are also processes for preparing the indicated compounds as well as their use for the preparation of medicaments.

公开(公告)号：SI0779288T1

公开(公告)日：2000-10-31

申请号：SI9630206

申请日：1996-12-02

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH CHRISTIAN DR ,  GERLACH UWE DR ,  MANIA DIETER DR ,  LINZ WOLFGANG DR ,  GOEGELEIN HEINZ DR ,  KLAUS ERIK DR ,  CRAUSE PETER DR

IPC: A61K31/35 ,  A61K31/352 ,  A61K31/353 ,  C07D311/58 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/4025 ,  A61K31/4412 ,  A61K31/443 ,  A61K31/445 ,  A61P9/00 ,  A61P9/06 ,  A61P9/10 ,  C07D311/64 ,  C07D311/70 ,  C07D405/12

Abstract: N-(4-Amidoalkyl-chroman-5-yl-sulphonyl)-urea or -thiourea derivatives of formula (I) and their salts are new. R1 = H, alkyl, alkoxy, F, Cl, Br, I, CF3, NH2, mono- or dialkylamino or alkylthio; R2a = H, Me or Et; R2b, R2d = H, Me or Et; or phenyl or benzyl (both optionally ring-substituted by 1-3 of halogen, Me, Et, OMe and OEt); R2c,R2e = H, Me or Et; R3 = H, alkyl, cycloalkyl, cycloalkylmethyl or CF3; n = 1 or 2; Z = O or S; A = phenyl (optionally substituted by 1-3 of halogen, Me, OMe, Et or OEt), a lactam residue of formula (a), 1-oxo-1,2,3,4-tetrahydroisoquinolin-2-yl, 1-oxo-per-hydro-isoquinolin-2-yl, 1-oxo-1,2-dihydro-iso-indol-2-yl or 1-oxo-per-hydro-iso-indol-2-yl; B = 3-6C alkylene or 3-6C alkenylene (both optionally substituted by 1-3 alkyl); unless specified otherwise alkyl moieties have 1-4C and cycloalkyl moieties 3-6C.

公开(公告)号：DE59209292D1

公开(公告)日：1998-05-28

申请号：DE59209292

申请日：1992-01-01

Applicant: HOECHST AG

Inventor： WAGNER ADALBERT DR ,  ENGLERT HEINRICH DR ,  KLEEMANN HEINZ-WERNER DR ,  GERHARDS HERMANN DR ,  SCHOELKENS BERNWARD PROF DR ,  BECKER REINHARD DR ,  LINZ WOLFGANG DR ,  CAILLE JEAN-CLAUDE ,  VEVERT JEAN-PAUL

IPC: A61K31/40 ,  A61K31/415 ,  A61K31/425 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/445 ,  A61K31/505 ,  A61K31/535 ,  A61K31/54 ,  A61K31/64 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P13/02 ,  A61P15/00 ,  A61P43/00 ,  C07D207/34 ,  C07D207/36 ,  C07D233/54 ,  C07D233/66 ,  C07D233/68 ,  C07D233/70 ,  C07D233/84 ,  C07D233/90 ,  C07D249/02 ,  C07D255/02 ,  C07D257/02 ,  C07D257/04 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D453/02 ,  C07D521/00

Abstract: Azole derivative of the general formula (I) in which A, L, O, R , X, Y, Z and q have the meanings given, a process for their preparation, pharmaceutical preparations and the use of the compounds are described. Azole derivatives of the formula I where the symbols have, for example, the following meanings: R = (C2-C10)-alkyl Z = nitrogen X and Y = independently of one another CR L = -CH2- q = zero or 1 A = biphenyl radical which is substituted, for example, by R R = halogen or hydrogen R = SO2-NH-CO-OR and R = phenyl, are highly active antagonists of angiotensin II receptors.

公开(公告)号：CZ283236B6

公开(公告)日：1998-02-18

申请号：CS347191

申请日：1991-11-15

Applicant: HOECHST AG

Inventor： HEITSCH HOLGER DR ,  HENNING RAINER DR ,  LINZ WOLFGANG DR ,  SCHOLKENS BERNWARD PROF DR ,  URBACH HANSJORG DR

IPC: A61K31/41 ,  A61K31/415 ,  A61K31/495 ,  A61K31/675 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P13/02 ,  A61P15/00 ,  A61P43/00 ,  C07D233/64 ,  C07D233/68 ,  C07D233/90 ,  C07D249/04 ,  C07D249/08 ,  C07D257/04 ,  C07D403/10

Abstract: The invention relates to a method for the treatment of cardiac and of vascular hypertrophy and/or hyperplasia by administration of angiotensin II receptor blockers, preferably of the imidazole, pyrrole, pyrazole, triazole or tetrazole type.

公开(公告)号：DE59307039D1

公开(公告)日：1997-09-11

申请号：DE59307039

申请日：1993-02-05

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH DR ,  MANIA DIETER DR ,  LANG HANS-JOCHEN DR ,  SCHOLZ WOLFGANG DR ,  LINZ WOLFGANG DR ,  ALBUS UDO DR

IPC: A61K31/155 ,  A61K31/165 ,  A61K31/445 ,  A61P1/16 ,  A61P3/08 ,  A61P3/10 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P13/02 ,  A61P15/00 ,  A61P35/00 ,  C07C279/22 ,  C07D213/65 ,  C07D295/14 ,  C07D295/155

Abstract: There are described benzoylguanidines of the formula I in which R(1) or R(2) is an amino group -NR(3)R(4), where R(3) and R(4) are equal to H, (cyclo)alkyl or R(3) is equal to phenyl-(CH2)p- where p = 0, 1, 2, 3 or 4, or phenyl, or R(3) and R(4) together can also be a methylene chain, and in which the other substituent R(1) or R(2) in each case is H, F, Cl, alkyl, alkoxy, CF3, CmF2m+1-CH2-, benzyl or phenoxy, and their pharmaceutically tolerable salts. The compounds according to the invention have very good antiarrhythmic properties, such as they show, for example, in the case of oxygen deficiency symptoms. The compounds are used as antiarrhythmic medicaments having a cardioprotective component for infarct prophylaxis and infarct treatment and also for the treatment of angina pectoris, where they preventively inhibit or strongly decrease the pathophysiological processes during the formation of ischaemically induced damage, in particular during the induction of ischaemically induced cardiac arrhythmias.

公开(公告)号：DK0410278T3

公开(公告)日：1994-05-24

申请号：DK90113712

申请日：1990-07-18

Applicant: HOECHST AG

Inventor： URBACH HANSJOERG DR ,  WAGNER ADALBERT DR ,  KLEEMANN HEINZ-WERNER DR ,  RUPPERT DIETER DR ,  LINZ WOLFGANG DR ,  KRAMER WERNER DR DR

IPC: C12N9/99 ,  A61K31/38 ,  A61K31/381 ,  A61K31/415 ,  A61K31/445 ,  A61K31/535 ,  A61K38/55 ,  A61P9/12 ,  C07C237/08 ,  C07C237/22 ,  C07D211/26 ,  C07D211/58 ,  C07D233/54 ,  C07D233/64 ,  C07D295/20 ,  C07D333/24 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12 ,  C07D521/00 ,  C07K1/113 ,  C07K5/06 ,  C07K5/065 ,  C07K5/078 ,  C07K14/81 ,  A61K37/64

Abstract: The present invention relates to compounds of the formula I in which A, R , R , R and n are defined as indicated in the description, to processes for the preparation thereof, to the use thereof as medicines and to pharmaceutical compositions containing these.

公开(公告)号：CZ9204033A3

公开(公告)日：1993-12-15

申请号：CS403392

申请日：1992-12-31

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH DR ,  MANIA DIETER DR ,  LANG HANS-JOCHEN DR ,  SCHOLZ WOLFGANG DR ,  LINZ WOLFGANG DR ,  ALBUS UDO DR

IPC: A61K31/155 ,  A61K31/165 ,  A61K31/445 ,  A61P1/16 ,  A61P3/08 ,  A61P3/10 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P13/02 ,  A61P15/00 ,  A61P35/00 ,  C07C279/22 ,  C07D213/65 ,  C07D295/14 ,  C07D295/155 ,  C07C279/20 ,  A61K31/40 ,  C07C277/08

CPC classification number: C07D295/155 ,  C07C279/22 ,  C07D213/65

公开(公告)号：DE59002721D1

公开(公告)日：1993-10-21

申请号：DE59002721

申请日：1990-08-08

Applicant: HOECHST AG

Inventor： LINZ WOLFGANG DR ,  SCHOELKENS BERNWARD PROF DR ,  SCHOLZ WOLFGANG DR ,  WIEMER GABRIELE DR ,  URBACH HANSJOERG DR ,  HENNING RAINER DR ,  TEETZ VOLKER DR

IPC: A61K38/55 ,  A61P9/08 ,  A61P9/10 ,  A61P43/00 ,  C07C237/12 ,  C07K5/06 ,  A61K37/64 ,  A61K37/02

Abstract: The invention relates to a method for the treatment of cardiac and of vascular hypertrophy and hyperplasia by administration of angiotensin converting enzyme inhibitors. Administration of compounds of the formula I (I) in which n is 1 or 2, R, R1, R2 and R3 are identical or different and each is hydrogen or an organic radical, and R4 and R5 form, together with the atoms carrying them, a mono-, bi- or tricyclic heterocyclic ring system, is preferred. The invention additionally relates to angiotensin converting enzyme inhibitors and to agents containing these for administration for the treatment of the abovementioned diseases.

公开(公告)号：CZ9004318A3

公开(公告)日：1993-05-12

申请号：CS431890

申请日：1990-09-05

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH CHRISTIAN DR ,  LANG HANS-JOCHEN DR ,  LINZ WOLFGANG DR ,  SCHOLKENS BERNWARD PROF DR ,  SCHOLZ WOLFGANG DR

IPC: C07C279/22 ,  A61K31/155 ,  A61K31/18 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/445 ,  A61K31/455 ,  A61K31/535 ,  A61K31/5375 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  C07C277/00 ,  C07C279/10 ,  C07C311/15 ,  C07C311/47 ,  C07C317/42 ,  C07C317/44 ,  C07C323/60 ,  C07C323/62 ,  C07C323/65 ,  C07C323/67 ,  C07D209/08 ,  C07D211/28 ,  C07D295/14 ,  C07D295/155 ,  C07D295/195 ,  C07D295/22 ,  C07D295/26

CPC classification number: C07D295/26 ,  C07C311/47 ,  C07C317/42 ,  C07C323/67 ,  C07C2601/06 ,  C07C2601/14 ,  C07D209/08 ,  C07D295/155